I was especially intrigued by their predictions for the top 50 products in the U.S. in 2016. Below is a handy chart comparing the 2016 list with 2010’s top sellers.
- The top 10 U.S. drugs in 2016 are projected to have total revenues of $31.0 billion, which would be $8.4 billion less than the top ten in 2010.
- Rituxan, the projected #1 drug in 2016, wouldn’t even make the 2010 top 10 list after adjusting for likely product price inflation.
Here’s my summary of the top 10 best-selling drugs as reported on pages 20 and 32 of the EvaluatePharma report.
As I have mentioned in previous posts, commercial strategies for specialty drugs are much more complex than strategies for traditional drugs. The options for service, financial, and channel flows are highly varied and must be customized for each product.
BTW, the report also has lots of neat corporate and product projections for key markets such as oncology products, anti-diabetics, and anti-rheumatics.
EvaluatePharma predicts that Pfizer, Sanofi and Novartis will be competing for the position of largest pharma company in the world in 2016. (See page 7.) All three are predicted to have prescription sales of about $50bn in 2016. GlaxoSmithKline, Roche, and Merck will be in the next tier will sales of $42 to $45 billion.
Of course, they wisely avoid predicting any M&A transactions that would scramble this list. Prediction is very difficult, especially if it's about the future.